Genoskin announces the launch of the ISR platform®, a new pre-clinical toolbox designed to study injection site reactions (ISR) in humans ahead of clinical trials.
Genoskin COVID-19 research preferred access program On Friday, March 13th 2020, Genoskin launched a preferred access program for all research teams actively developing therapeutic and vaccine technologies for the COVID-19 pandemic. The World Health Organization (WHO) officially declared on March 11th, the outbreak of COVID-19 a pandemic. The disease caused by SARS-CoV-2 has spread globally. Over 130,000 individuals are affected so